Gilead's first cancer drug, Zydelig ... Our business relationships in no way influence the funds or stocks discussed here. The Morningstar Ultimate Stock-Pickers Team does not own shares in any of the securities mentioned above. Find out …
In DepthMorningstar20d
In early 2014, the stock price of a then lesser-known biotech called Intercept ... Company pipelines have also advanced, with four candidates from Intercept, Gilead, Allergan and Genfit now in Phase 3 testing. If all goes well, a drug could …
It appeared that Gilead Sciences, Inc. (NASDAQ:GILD) had turned the corner earlier this year after a long slump. Just three years ago, Gilead reached a high of $120 per share at the height of its HCV treatment sales surge. Then its revenues …
From 2012 to 2015, Gilead's Hepatitis C cure turbo-charged its stock, inspiring …
CNBC1mon
It appeared that Gilead Sciences, Inc. (NASDAQ:GILD) had turned the corner earlier this year after a long slump. Just three years ago, Gilead reached a high of $120 per share at the height of its HCV treatment sales surge. Then its revenues …
After releasing downright worrisome first-quarter results, Gilead Sciences (NASDAQ: GILD) has seen its shares drop by a noteworthy 11.7% in the past few days. The big concern is that Gilead's ailing hepatitis C franchise has yet to stabilize …
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 17 major stocks, including BP (BP), Gilead (GILD), Enterprise Products (EPD) and Colgate (CL). …
After releasing downright worrisome first-quarter results, Gilead Sciences (NASDAQ: GILD) has seen its shares drop by a noteworthy 11.7% in the past few days. The big concern is that Gilead's ailing hepatitis C franchise has yet to stabilize …